Cargando…

The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis

BACKGROUND: To comprehensively evaluate the treatment efficacy and safety of silymarin for patients with glucose/lipid metabolic dysfunction using a meta-analysis. METHODS: A systematic literature search in PubMed, EMBASE and Cochrane Library databases was performed up to October 1, 2019. STATA 13.0...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Fengyan, Gao, Feng, Zhou, Shengxue, Wang, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535778/
https://www.ncbi.nlm.nih.gov/pubmed/33019400
http://dx.doi.org/10.1097/MD.0000000000022249
_version_ 1783590457671942144
author Xiao, Fengyan
Gao, Feng
Zhou, Shengxue
Wang, Lina
author_facet Xiao, Fengyan
Gao, Feng
Zhou, Shengxue
Wang, Lina
author_sort Xiao, Fengyan
collection PubMed
description BACKGROUND: To comprehensively evaluate the treatment efficacy and safety of silymarin for patients with glucose/lipid metabolic dysfunction using a meta-analysis. METHODS: A systematic literature search in PubMed, EMBASE and Cochrane Library databases was performed up to October 1, 2019. STATA 13.0 software was used to estimate pooled standardized mean difference (SMD) and 95% confidence interval (95% CI). RESULTS: Sixteen studies involving 1358 patients were identified. Overall meta-analysis showed that compared with control, silymarin significantly reduced levels of fasting blood glucose (SMD: −1.27, 95% CI = [−1.78, −0.76]; P < .001), homeostatic model assessment for insulin resistance (SMD: −0.41, 95% CI = [−0.70, −0.12]; P = .005), hemoglobin A1c (SMD: −1.88, 95% CI = [−2.57, −1.20]; P < .001), total cholesterol (SMD: −1.13, 95% CI = [−1.82, −0.77]; P < .001), triglyceride (SMD: −0.37, 95% CI = [−0.69, −0.05]; P = .025), low-density lipoprotein-cholesterol (SMD: −1.30, 95% CI = [−1.93, −0.67]; P < .001), C-reactive protein (SMD: −0.63, 95% CI = [−1.01, −0.27]; P = .001), and increased high-density lipoprotein-cholesterol (SMD: 0.17, 95% CI = [0.05, 0.29]; P = .005), but had no impacts on function indicators of liver and kidney (alanine transaminase, aspartate aminotransferase, creatinine phosphokinase, creatinine) and the complication rate. Subgroup analyses indicated that insulin (which was negative in overall analysis) was significantly decreased in patients undergoing silymarin monotherapy (SMD: −2.03, 95% CI = [−3.03, −1.04]; P = .044) for more than 3 months (SMD: −0.01, 95% CI = [−0.25, −0.24]; P = .035). CONCLUSION: Supplementation of silymarin may be effective and safe for the management of diabetes mellitus and hyperlipidemia.
format Online
Article
Text
id pubmed-7535778
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75357782020-10-14 The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis Xiao, Fengyan Gao, Feng Zhou, Shengxue Wang, Lina Medicine (Baltimore) 3800 BACKGROUND: To comprehensively evaluate the treatment efficacy and safety of silymarin for patients with glucose/lipid metabolic dysfunction using a meta-analysis. METHODS: A systematic literature search in PubMed, EMBASE and Cochrane Library databases was performed up to October 1, 2019. STATA 13.0 software was used to estimate pooled standardized mean difference (SMD) and 95% confidence interval (95% CI). RESULTS: Sixteen studies involving 1358 patients were identified. Overall meta-analysis showed that compared with control, silymarin significantly reduced levels of fasting blood glucose (SMD: −1.27, 95% CI = [−1.78, −0.76]; P < .001), homeostatic model assessment for insulin resistance (SMD: −0.41, 95% CI = [−0.70, −0.12]; P = .005), hemoglobin A1c (SMD: −1.88, 95% CI = [−2.57, −1.20]; P < .001), total cholesterol (SMD: −1.13, 95% CI = [−1.82, −0.77]; P < .001), triglyceride (SMD: −0.37, 95% CI = [−0.69, −0.05]; P = .025), low-density lipoprotein-cholesterol (SMD: −1.30, 95% CI = [−1.93, −0.67]; P < .001), C-reactive protein (SMD: −0.63, 95% CI = [−1.01, −0.27]; P = .001), and increased high-density lipoprotein-cholesterol (SMD: 0.17, 95% CI = [0.05, 0.29]; P = .005), but had no impacts on function indicators of liver and kidney (alanine transaminase, aspartate aminotransferase, creatinine phosphokinase, creatinine) and the complication rate. Subgroup analyses indicated that insulin (which was negative in overall analysis) was significantly decreased in patients undergoing silymarin monotherapy (SMD: −2.03, 95% CI = [−3.03, −1.04]; P = .044) for more than 3 months (SMD: −0.01, 95% CI = [−0.25, −0.24]; P = .035). CONCLUSION: Supplementation of silymarin may be effective and safe for the management of diabetes mellitus and hyperlipidemia. Lippincott Williams & Wilkins 2020-10-02 /pmc/articles/PMC7535778/ /pubmed/33019400 http://dx.doi.org/10.1097/MD.0000000000022249 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 3800
Xiao, Fengyan
Gao, Feng
Zhou, Shengxue
Wang, Lina
The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
title The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
title_full The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
title_fullStr The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
title_full_unstemmed The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
title_short The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis
title_sort therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: a meta-analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535778/
https://www.ncbi.nlm.nih.gov/pubmed/33019400
http://dx.doi.org/10.1097/MD.0000000000022249
work_keys_str_mv AT xiaofengyan thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT gaofeng thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT zhoushengxue thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT wanglina thetherapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT xiaofengyan therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT gaofeng therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT zhoushengxue therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis
AT wanglina therapeuticeffectsofsilymarinforpatientswithglucoselipidmetabolicdysfunctionametaanalysis